Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

Affiliations

• ¹ Weill Cornell Medical College, New York, NY; New York Presbyterian Hospital, New York. gar2001@med.cornell.edu.
• ² Ulm University Hospital, Ulm.
• ³ Kent and Canterbury Hospital, Canterbury.
• ⁴ Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP) and Institut de Recherche Saint-Louis, Université de Paris, Paris.
• ⁵ The University of Texas MD Anderson Cancer Center, Houston.
• ⁶ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
• ⁷ AZ Sint-Jan Brugge-Oostende AV, Bruges.
• ⁸ University Hospital Brno, Brno, Czech Republic.
• ⁹ SLK-Kliniken GmbH, MOLIT Institute for Personalized Medicine, Heilbronn.
• ¹⁰ Wilmot Cancer Institute, University of Rochester, New York.
• ¹¹ Hospital Universitario Central de Asturias, Oviedo.
• ¹² Chang Gung Medical Foundation, Kaohsiung.
• ¹³ Evidera, Waltham.
• ¹⁴ Celgene, a Bristol-Myers Squibb Company, Boudry.
• ¹⁵ Bristol Myers Squibb, Princeton, NJ; University of Kansas Medical Center, Kansas City.
• ¹⁶ Bristol Myers Squibb, Princeton.
• ¹⁷ The Alfred Hospital and Monash University, Melbourne.